Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
Infliximab, a TNF-α inhibitor, is a widely used biologic ... psoriatic arthritis, and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in ...